CompletedPhase 2

Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.

Egypt48 participantsStarted 2017-09-30

Plain-language summary

The present randomized, controlled, parallel-grouped trial includes 48 patients (aged 18 to 75 years) suffering from oral potential premalignant lesions. Patients will be randomly assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B: Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Inclusion Criteria: * Patients with age range 18-75 years. * Patients with any known potentially malignant lesion confirmed histologically and clinically. Exclusion Criteria: * Patients with systemic illness. * Patients received previous treatment for the condition. * Current malignancy. * Pregnant or lactating women. * Hypersensitivity to the intervention.

What they're measuring

clinical response

Timeframe: baseline

clinical response

Timeframe: 3 months

Trial details

NCT IDNCT03208790

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-03-12

View on ClinicalTrials.gov More Premalignant Lesion trials